Stockscreener 앱 받기
34.17
3.20%
-1.13
시간 외 거래:
34.45
0.28
+0.82%
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
Buy Rating for Structure Therapeutics, Inc.: Potential Disruption in Obesity Treatment with Amylin Agonists - TipRanks
Structure Therapeutics Reports Q3 2025 Financial Results - MSN
Buy Rating on Structure Therapeutics, Inc. Driven by Aleniglipron’s Potential in the Obesity Market - TipRanks
Avago, Google among market cap stock movers on Wednesday By Investing.com - Investing.com South Africa
Avago, Google among market cap stock movers on Wednesday - Investing.com
Structure Therapeutics Inc ADR (GPCR) is looking forward to a strong quarter - Setenews
A look into Viasat, Inc (VSAT)’s deeper side - Setenews
Structure Therapeutics stock hits 52-week high at 37.66 USD By Investing.com - Investing.com Nigeria
Structure Therapeutics stock hits 52-week high at 37.66 USD - Investing.com
BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts - Finviz
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Oral Proteins and Peptides Market Know the Scope and Trends - industrytoday.co.uk
Why Structure Therapeutics Shares Are On The Rise - TipRanks
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Nothing is Better Than Structure Therapeutics Inc ADR (GPCR) stock at the moment - Setenews
Buy Rating for Structure Therapeutics: Potential Breakthrough in Obesity Treatment with Aleniglipron - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zymeworks (ZYME), MBX Biosciences, Inc. (MBX) and Lemaitre Vascular (LMAT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA), Astrana Health (ASTH) and Viatris (VTRS) - The Globe and Mail
Decoding Structure Therapeutics Inc (GPCR): A Strategic SWOT Ins - GuruFocus
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Positive Buy Rating for Structure Therapeutics Driven by Promising Product Outlook and Strong Financial Position - TipRanks
Structure Therapeutics : Corporate Presentation (November 2025) - MarketScreener
Entero Therapeutics’ Board Governance Structure Update - TipRanks
[8-K] Structure Therapeutics Inc. Reports Material Event | GPCR SEC FilingForm 8-K - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) on track for 36-week GLP-1 data year-end 2025 - Stock Titan
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights - The Globe and Mail
CapEx per share of Structure Therapeutics, Inc. Sponsored ADR – NASDAQ:GPCR - TradingView
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Wall Street analysts’ outlook for Structure Therapeutics Inc ADR (GPCR) - setenews.com
Structure Therapeutics (GPCR) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Pier Capital LLC Cuts Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Up 9.2%Still a Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
Strong Market Demand and Convenience Drive Buy Rating for Structure Therapeutics - TipRanks
What is Structure Therapeutics Inc ADR (GPCR) Stock Return on Shareholders’ Capital? - Setenews
11,000 Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR Acquired by Allianz Asset Management GmbH - MarketBeat
Allianz Asset Management GmbH Has $252,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - Defense World
Allianz Asset Management GmbH Purchases New Holdings in Tarsus Pharmaceuticals, Inc. $TARS - Defense World
Jazz Pharmaceuticals (NASDAQ: JAZZ) names Ted W. Love, M.D., to board Dec 1, 2025 - Stock Titan
Structure Therapeutics (NASDAQ:GPCR) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now? - NewsBreak: Local News & Alerts
Critical Survey: Alkermes (NASDAQ:ALKS) and Structure Therapeutics (NASDAQ:GPCR) - Defense World
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Kura Oncology (KURA) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Align Tech (ALGN) and ProQR (PRQR) - The Globe and Mail
Pacific Heights Asset Management LLC Acquires New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Trading Systems Reacting to (GPCR) Volatility - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Wuxi Biologics (Cayman) (OtherWXIBF) and Avalo Therapeutics (AVTX) - The Globe and Mail
(PDF) Structural basis for chemotype diversity in small molecule GLP-1 receptor agonist drug discovery - researchgate.net
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Abbott Laboratories (ABT) and Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Aclaris Therapeutics (ACRS) - The Globe and Mail
Structure Therapeutics Inc ADR (GPCR) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Structure Therapeutics Inc. (GPCR): Investor Outlook With A 142% Potential Upside - DirectorsTalk Interviews
Griffin Asset Management Inc. Makes New Investment in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $68.67 - Defense World
Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) PT at $68.67 - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Structure Therapeutics' (GPCR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
0.53%
1.88%
자본화:
|
볼륨(24시간):